HemOnc Today honored its inaugural class of Next Gen Innovators during the ASH Annual Meeting and Exposition.
The Next Gen Innovators are a highly select group of early career hematologists and oncologists who have advanced their field through innovative approaches in the clinical and research settings.
HemOnc Today Editorial Board members, along with other leaders in the field, nominated exceptional individuals for this honor.
The Next Gen Innovators initiative will help showcase the talents and expertise of these rising stars in hematology and oncology by giving them a voice in our coverage and encouraging them to share viewpoints about key issues and challenges in the specialty.
“We would like to congratulate the members of the Next Gen Innovators and thank them for all of their individual accomplishments and contributions to the specialty,” said Joan-Marie Stiglich, ELS, Chief Content Officer of SLACK Incorporated, the publisher of HemOnc Today. “We look forward to working with this unique group of early career hematologists and oncologists to help bring a broader scope and perspective to our readers. It’s another step in our ongoing commitment to the entire hematology and oncology community.”
Additional HemOnc Today Next Gen Innovators will be announced in the spring. If you would like to nominate yourself or a colleague, please email Editorial Director Mark Leiser at email@example.com.
The inaugural members of HemOnc Today’s Next Gen Innovators are:
- Allistair Abraham, MD, of Children’s National Medical Center and George Washington University;
- Ibrahim Aldoss, MD, of City of Hope;
- Matthew J. Barth, MD, of Roswell Park Cancer Institute and University at Buffalo;
- Giada Bianchi, MD, of Dana-Farber Cancer Institute;
- Andrew M. Brunner, MD, of Massachusetts General Hospital and Harvard Medical School;
- Huynh Cao, MD, of Loma Linda University Medical Center;
- George Chen, MD, of Roswell Park Cancer Institute and University at Buffalo;
- Adam C. Cuker, MD, MS, of University of Pennsylvania;
- Andrew Dunbar, MD, of Memorial Sloan Kettering Cancer Center;
- Areej El-Jawahri, MD, of Massachusetts General Hospital and Harvard Medical School;
- Lindsey A. George, MD, of University of Pennsylvania and Children’s Hospital of Philadelphia;
- Aaron T. Gerds, MD, MS, of Cleveland Clinic Taussig Cancer Institute;
- Damian J. Green, MD, of University of Washington and Fred Hutchinson Cancer Research Center;
- Nicole R. Grieselhuber, MD, PhD, of The Ohio State University;
- Elizabeth A. Griffiths, MD, of Roswell Park Cancer Institute and University at Buffalo;
- Michael Grunwald, MD, of Levine Cancer Institute at Carolinas HealthCare System;
- Gabriela Hobbs, MD, of Massachusetts General Hospital;
- Laura E. Hogan, MD, of Stony Brook University;
- Julie Kanter, MD, of Medical University of South Carolina;
- Dan Landau, MD, PhD, of Weill Cornell Medicine and New York Genome Center;
- Gabriel Mannis, MD, of Helen Diller Family Comprehensive Cancer Center at University of California, San Francisco;
- Rakhi P. Naik, MD, MHS, of Johns Hopkins Medicine;
- Aziz Nazha, MD, of Cleveland Clinic Taussig Cancer Institute;
- Ifeyinwa Osunkwo, MD, MPH, of Levine Cancer Institute at Carolinas HealthCare System and The University of North Carolina at Chapel Hill;
- Steven Park, MD, of Levine Cancer Institute at Carolinas HealthCare System and The University of North Carolina at Chapel Hill;
- Vinay K. Prasad, MD, MPH, of Oregon Health & Science University;
- Deva Sharma, MD, MS, of Vanderbilt University;
- Nicholas Short, MD, of The University of Texas MD Anderson Cancer Center;
- Surbhi Sidana, MD, of Mayo Clinic in Rochester, Minnesota;
- Eric L. Smith, MD, PhD, of Memorial Sloan Kettering Cancer Center;
- Deborah M. Stephens, DO, of Huntsman Cancer Institute at University of Utah;
- Carlyn Tan, MD, of Fox Chase Cancer Center; and
- Pallawi Torka, MD, of Roswell Park Cancer Institute.